PBMC as Biomarkers of Diabetic Cardiomyopathy

Recruiting Observational Study
Type 2 Diabetes Metabolic Syndrome Heart Failure With Preserved Ejection Fraction Heart Failure With Mildly Reduced Ejection Fraction
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
40 – 85
Sex
Any
Study type
Observational
Participants needed
175 (estimated)
Sponsor
Hospices Civils de Lyon · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Type 2 diabetes (T2D), especially when associated with metabolic syndrome (MS) is at high risk to develop heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), and the specific impact of T2D+MS in cardiac function impairment is usually known as "diabetic cardiomyopathy" (DC). Cardiac remodelling (ie hypertrophy) and subtle myocardia…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Inclusion criteria common to the 4 groups: * Patient attending a scheduled cardiology or endocrinology follow-up visit * Patient fasting for blood sampling * Male or female aged 40 to 85 years inclusive * Patient not opposing participation in this research * Patient agreeing to…
Contacts

Hélène THIBAULT, PU,PH

0427856691

Helene.thibault@chu-lyon.fr

CONTACT

Julia CANTERINI

0427856628

Julia.canterini@chu-lyon.fr

CONTACT